Printer Friendly

Researchers at University of Illinois discover monobody that can block oncogene's activity.

M2 PHARMA-November 10, 2016-Researchers at University of Illinois discover monobody that can block oncogene's activity


Researchers at the University of Illinois in Chicago have found a monobody that can block the oncogene's activity, it was reported yesterday.

RAS mutations appear in about 30% of all cancers. They are also present in nearly 90% of pancreatic cancers and occur frequently in colon cancer, lung cancer and melanoma. During their research, the scientists created a synthetic binding protein in the lab, named NS1 monobody and found that it can inhibit the RAS proteins.

The university's John O'Bryan PhD stated that the team did not look for a drug or particularly for an inhibitor. He added that the team had utilised a type of protein-engineering technology called monobody technology to identify RAS regions that are critical for its function. O'Bryan concluded that the new insights could help in the development of new therapeutic methods for cancer treatment by the interference of mutant RAS function in cancer cells by the NS1 monobody.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Nov 10, 2016
Previous Article:Medicure reports financial results for quarter ended 30 September 2016.
Next Article:Mylan reports financial results for nine months ended 30 September 2016.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters